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BACKGROUND: It has been reported that there is an increased risk of cancer in individuals with elevated levels of serum g-glutamyl
transferase (GGT).
METHODS: In the Guernsey Breast Cancer Cohort Study, GGT was measured in sera from 1803 normal women. Among these
women, 251 subsequently developed cancer, of whom 96 developed breast cancer.
RESULTS: After adjustment for age at entry, height, weight, age at menarche and first birth with nulliparity, there was a highly significant
relationship between elevated GGT and breast cancer risk. In the highest quartile, the hazard ratio (HR) was 2.17 (95% confidence
interval (CI): 1.19, 3.93). When subdivided by menopausal status, there was a reduced non-significant effect in postmenopausal
women, whereas for premenopausal women in the highest quartile, HR was 3.81 (95% CI: 1.37, 10.59). Premenopausal women with
serum GGT levels above the normal range had a significantly elevated HR of 4.90 (95% CI: 1.86, 12.94).
CONCLUSIONS: These results suggest that premenopausal women with high normal (above median) serum GGT or elevated levels
(p40IUl
 1) are at increased risk of breast cancer and might benefit from close surveillance, possibly with breast magnetic resonance
imaging scans. Serum GGT may mark previous exposure to carcinogens and lead to the identification of DNA adducts involved in
mammary carcinogenesis.
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The enzyme g-glutamyl transferase (GGT, EC 2.3.2.2) uniquely
enables glutathione (GSH) catabolism by hydrolysing the
g-glutamyl bond between glutamate and cysteine. The enzyme is
widely present on the external surface of most cells but has been
particularly studied as a marker of hepatic dysfunction (Teschke
et al, 1977). However, there is evidence that GGT is implicated in
other major diseases, including cardiovascular disease (Ruttmann
et al, 2005) and diabetes (Lee et al, 2004). In the Vorarlberg study,
with 163944 adults followed up for a median of 12 years, high GGT
was significantly associated with risk of death from cardiovascular
disease (Strasak et al, 2008). In a large Finnish cohort study of
20158 individuals, within the normal range of GGT, there was a
dose–response relationship between GGT levels and risk of type II
diabetes in both men and women (Lee et al, 2004).
A series of 283438 first attendants at the Vienna General
Hospital gave blood for GGT analysis and were followed up for up
to 13 years to determine all-cause mortality (Kazemi-Shirazi et al,
2007). For both males and females with elevated serum GGT, there
was significantly increased mortality from all causes, cardiovas-
cular disease, hepatobiliary disease and cancer. Mortality risk was
particularly increased for those aged o30 years.
Recently, Strasak et al (2008) examined cancer incidence in
relation to GGT levels among the 92983 females participating in
the Vorarlberg study. After a median follow-up of 13.5 years, 4884
cancer cases were diagnosed. The normal low level of GGT was
taken as o17.99Ul
 1 and, compared with this, there was a highly
significant increase in hazard ratio (HR) for cancer incidence
with increasing levels of GGT, so that among those with levels
472Ul
 1, HR was 1.43 (95% confidence interval (CI): 1.28–1.61).
In terms of site specificity, elevated GGT was associated with
cancers of the digestive tract, respiratory tract, breast/female
genital organs and haematopoetic system.
To investigate the relationship between GGT levels and risk of
malignancy, particularly breast cancer, assays have been carried
out on serum samples from 1888 women who participated in the
Guernsey Breast Cancer Cohort Study, of whom 251 were
subsequently diagnosed with cancer.
METHODS
The Guernsey Cohort Study has been underway since 1961 with the
aim of identifying risk factors for breast cancer in a normal
population (Wang et al, 2000). In the fourth phase of the study,
which recruited volunteers between 1986 and 1990, 4714 women
participated, all of whom were aged 432 years and were residents
of Guernsey. They attended the Imperial Cancer Research Fund
(now Cancer Research, UK) Laboratory in Guernsey and
completed a detailed questionnaire with regard to their previous
medical and reproductive history.
After the interview, blood pressure, height and weight were
measured and then 60ml of blood was taken (50ml without
anticoagulant and 10ml with EDTA). After centrifugation, aliquots
of both serum and plasma were prepared. Aliquots of 2ml were
stored at  201C and subsequently assayed in batches. Serum
samples were used in this study. Serum GGT was measured by JPS
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sLaboratories (formerly London, UK) using a routine kinetic
colorimetric method. The coefficient of variation was 6% during
the assay period.
Assays were performed on 1888 samples that were randomly
selected. However, 68 women had been previously diagnosed
with cancer (excluding non-melanoma skin cancer), and a
further three were found to have breast cancer during the study-
screening process. These were excluded from the analysis. A
further 14 samples were eliminated during the statistical analysis
because of missing values in covariates. Thus, the final analysis
was performed on 1803 samples.
Follow-up of the cohort is still active and information on cancer
incidence is obtained regularly through pathology reports from
the only pathology laboratory in Guernsey, as well as from death
certificates and data from the South West Cancer Registry. The
study was approved by all relevant ethics committees and the
women provided written consent.
Cox proportional hazards regression models were fitted to
estimate HRs for risk of any cancer (except non-melanoma skin
cancer), risk of breast cancer and risk of any cancer excluding
breast, using the Stata statistical package (Stata Corporation,
2003). For breast cancer, all values were adjusted for age at entry,
height at entry, weight at entry, age at menarche and age at first
birth with nulliparity. For other cancers, values were adjusted for
age at diagnosis and weight.
RESULTS
The distribution characteristics of GGT in this population are
shown in Table 1. Postmenopausal women had slightly but
significantly higher values than premenopausal women. Thus,
in the analyses by menopausal status, the quartiles used are
appropriate for each group. GGT was also found to be positively
and significantly associated with body mass index and weight in
premenopausal women, and with weight in postmenopausal
women. It was not found to be significantly associated with parity
or age at first birth in either menopausal group.
The features of the 1803 participants, including the 96
subsequently diagnosed with breast cancer, are given in Table 2.
The breast cancers were diagnosed between 21 months and
20 years after the blood sample was taken.
To determine whether GGT level was related to overall risk of
cancer in this cohort, an analysis was conducted on all incident
cancers. There were 251 cancers (breast 96, colorectal 21, lung 17,
ovary 15, melanoma 14, endometrium 12, lymphoma 8, pancreas 8,
oesophagus 7, stomach 4, bladder 4, cervix 4 and kidney 2). Results
are shown in Table 3, which indicate that, overall, there was a
significant increase in risk among those with GGT levels above the
normal range. However, when the breast cancer cases were
Table 1 The distribution characteristics of GGT in the whole population
and by menopausal status
All Premenopausal Postmenopausal
N 1803 828 944
Minimum value 1 1 1
Maximum value 96 95 96
Median 11 9 13
Interquartile range 8–17 7–14 9–19
Abbreviation: GGT¼g-glutamyl transferase.
Table 2 Characteristics of individuals participating in the Guernsey
Breast Cancer Cohort Study included in the GGT analyses
Feature Number (%)
Age (years)
32–40 59 (3)
41–50 812 (45)
51–60 485 (27)
61–70 288 (16)
470 159 (9)
Weight (kg) mean±s.d. 65.1±10.9
Height (cm) mean±s.d. 160.8±6.2
BMI mean±s.d. 25.2±4.0
Parity and age at first full-term delivery
Nulliparous 228 (13)
AFB p20 243 (13)
AFB 21–30 1178 (65)
AFB 430 154 (9)
Menopausal status
Premenopausal 828 (46)
Postmenopausal 944 (52)
Uncertain 31 (2)
Age at menarche (years)
p13 1121 (62)
X14 682 (38)
Abbreviations: AFB¼age at first full term delivery; BMI¼body mass index; GGT¼
g-glutamyl transferase.
Table 3 GGT and subsequent cancer (Cox regression adjusted by age and weight at entry)
All incident cancers All cancers, except breast
All Pre Post All Pre Post
(N/cases) (1803/251) (828/88) (944/160) (1803/155) (828/48) (944/105)
GGT in quartiles P¼0.28 P¼0.21 P¼0.59 P¼0.24 P¼0.82 P¼0.29
Q1 (lowest) 1.00 1.00 1.00 1.00 1.00 1.00
Q2 1.26 (0.88, 1.81) 1.59 (0.91, 2.79) 0.99 (0.62, 1.60) 1.15 (0.75, 1.78) 1.32 (0.66, 2.64) 0.96 (0.54, 1.69)
Q3 1.12 (0.78, 1.61) 1.72 (0.95, 3.12) 0.84 (0.53, 1.32) 0.68 (0.42, 1.11) 0.91 (0.38, 2.17) 0.61 (0.35, 1.09)
Q4 1.34 (0.96, 1.89) 1.67 (0.92, 3.01) 1.11 (0.73, 1.69) 1.05 (0.69, 1.60) 0.92 (0.40, 2.11) 0.99 (0.60, 1.63)
GGT by median values P¼0.40 P¼0.13 P¼0.99 P¼0.24 P¼0.52 P¼0.34
Below median 1.00 1.00 1.00 1.00 1.00 1.00
Above median 1.11 (0.86, 1.44) 1.39 (0.91, 2.14) 0.98 (0.72, 1.35) 0.82 (0.59, 1.14) 0.82 (0.44, 1.51) 0.83 (0.56, 1.22)
GGT by normal range P¼0.053 P¼0.023 P¼0.28 P¼0.99 P¼0.82 P¼0.93
In normal range 1.00 1.00 1.00 1.00 1.00 1.00
Above normal range 1.57 (0.99, 2.49) 2.63 (1.14, 6.05) 1.35 (0.78, 2.35) 1.00 (0.49, 2.05) 0.80 (0.11, 5.78) 1.04 (0.48, 2.24)
Abbreviation: GGT¼g-glutamyl transferase; Q1, first quartile; Q2, second quartile; Q3, third quartile; Q4, fourth quartile. Values in bold type represent significant P-values (Po0.05).
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sremoved from the analysis, no significant relationship was
observed between GGT and cancer risk.
As Table 4 shows, when GGT values were divided into quartiles,
within the normal range, there was a highly significant increase in
HR, which rose to 2.17 (95% CI: 1.19, 3.93) in the highest quartile.
When analysed on the basis of GGT levels below and above the
median, the latter group had an HR of 1.88 (95% CI: 1.23, 2.87).
Lim et al (2007) found a close association between GGT and
obesity. We also found a significant association between GGT and
weight, and as there is also a significant association between
postmenopausal obesity and breast cancer risk (London et al, 1989),
the results were re-analysed on the basis of menopausal status at the
time of entry into the study. Premenopausal women were defined as
those women who were still menstruating or women who had had a
hysterectomy (± one ovary removed) and who were aged p50
years. Postmenopausal women was defined as those women who
were past natural menopause or have had both ovaries removed, or
who have had a hysterectomy and were 450 years of age.
The results were paradoxical. As Table 5 shows, there was no
relationship between GGT and breast cancer risk in those women
who were postmenopausal at the time of entry. The effect was
confined to those who were premenopausal and those in the
highest quartile who had an HR of 3.81 (95% CI: 1.37, 10.59).
The group with GGT levels above the median had an HR of 2.46
(1.22, 4.96). When those with GGT levels above the normal range
(p40IUl
 1) were compared with those within the normal range,
HR was 4.90 (95% CI: 1.86, 12.94) P¼0.001. There was no
relationship between disease interval and levels of GGT.
DISCUSSION
This study found a significant relationship between GGT and
overall risk of cancer, which disappeared when breast cancer
cases were removed from the analysis. After adjustment for
known risk factors, including weight, there was an independent
significant relationship between elevated GGT and subsequent risk
of breast cancer. However, no effect was seen in postmenopausal
women, whereas for premenopausal women, HR was 3.82 for the
highest quartile. Those premenopausal women with serum GGT
levels above the normal range had a significantly elevated HR
of 4.90.
A limitation of the study is that we do not have information of
alcohol intake among the participants. However, the blood samples
were collected between 1986 and 1990 before there was a major
increase in alcohol use in women.
Because this was a prospective study, with samples being taken
before development of breast cancer, it is likely that GGT elevation
was not a result of malignant transformation, but possibly had
a role in this process. Although GGT has been implicated in
malignancy, this is the first study to show the specific effect
in terms of breast cancer risk.
g-Glutamyl transferase catalyses hydrolysis and transpeptidation
of extracellular GSH, thereby having a central role in maintaining
glutathione homeostasis. GSH is an antioxidant, protecting cells
against oxidative stress. Generation of the more reactive glycyl-
cysteine reduces ferrous to ferric iron, thereby starting an iron
redox cycling process (Stark et al, 1993). In addition, GSH
functions as a detoxifier of drugs and carcinogens by means of the
glutathione transferase gene superfamily (Hayes and Pulford,
1995). As GGT is the sole enzyme capable of cleaving the
g-glutamyl bond in GSH, areas of increased GGT may result in
metal ion reduction and redox cycling. GSH/GGT-dependent
pro-oxidant reaction has been found to modulate the transduction
of proliferative/apoptotic signals (Accaoui et al, 2000). The
hydrogen peroxide released by GGT produces an anti-apoptotic
Table 5 Breast cancer risk and GGT by menopausal status (adjusted by age, age at first birth/nulliparity, age at menarche, height and weight)
Premenopausal Postmenopausal
HR (95% CI) P-value HR (95% CI) P-value
N (cases) 828 (40) 944 (55)
GGT in quartiles
Q1 1.00 0.017 1.00 0.56
Q2 2.19 (0.81, 5.90) 1.16 (0.48, 2.81)
Q3 3.92 (1.52, 10.10) 1.59 (0.73, 3.43)
Q4 3.82 (1.48, 9.89) 1.53 (0.71, 3.29)
GGT by median value
Below median (11.0IUl
 1) 1.00 0.003 1.00 0.19
Above median 2.68 (1.40, 5.15) 1.46 (0.83, 2.55)
GGT by normal range
In normal range (p40 IUl
 1) 1.00 0.001 1.00 0.11
Above normal range 4.90 (1.86, 12.94) 1.91 (0.86, 4.25)
Abbreviation: CI¼confidence interval; HR¼hazard ratio; GGT¼g-glutamyl transferase; Q1, first quartile; Q2, second quartile; Q3, third quartile; Q4, fourth quartile. Quartiles for GGT by
menopausal status as given below Table 2. Median value for premenopausal¼9IUl
 1, for postmenopausal¼13IUl
 1. Values in bold type represent significant P-values (Po0.05)
Table 4 Hazard ratio for breast cancer risk in relation to level of serum
GGT (adjusted by age, age at first birth/nulliparity, age at menarche, height
and weight)
All
HR (95% CI) P-value
N (cases) 1803 (96)
GGT in quartiles
Q1 (p8.0IUl
 1) 1.00 0.011
Q2 (8.1–11.0IUl
 1) 1.55 (0.81, 2.97)
Q3 (11.1–14.0IUl
 1) 2.41 (1.33, 4.35)
Q4 (414.0IUl
 1) 2.17 (1.19, 3.93)
GGT by median value
Below median (11.0IUl
 1) 1.00 0.004
Above median 1.88 (1.23, 2.87)
GGT by normal range
In normal range (p40IUl
 1) 1.00 0.003
Above normal range 2.50 (1.36, 4.60)
Abbreviation: CI¼confidence interval; HR¼hazard ratio; GGT¼g-glutamyl trans-
ferase; Q1, first quartile; Q2, second quartile; Q3, third quartile; Q4, fourth quartile.
Values in bold type represent significant P-values (Po0.05)
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seffect in U937 histiocytic lymphoma cells in vitro (Dominici et al,
2003). In a recent study of human GGT-transfected melanoma
cells, Corti et al (2009) reported that increased levels of GGT led to
higher rates of DNA damage and more oxidised bases.
Studies on human breast cancers have given mixed results,
probably because menopausal status and age were not taken into
account. Dawson et al (1979) reported significantly elevated levels of
GGT in 10 invasive cancers compared with normal or non-involved
peritumoural tissue, but found even higher levels in fibroadenomas.
Levine et al (1983) compared 67 normal/benign and 108 cancers and
found a gradation between benign, atypical and malignant lesions.
Cancers that stained showed diffuse cytoplasmic staining. In a series
of 79 invasive cancers, using a polyclonal antibody, Durham et al
(1997) reported that 29% showed no immunoreactivity for GGT,
whereas all benign lesions expressed GGT.
Lee and Jacobs (2006) measured persistent organic pollutant
(POP) concentrations and GGT activity in sera from participants
in the National Health and Nutrition Examination Survey. Of the
six most frequently detected POPs, there was a positive association
between POP and GGT concentrations within the normal range for
five of the POPs. In the same population, there was also a graded
association of blood levels of lead and cadmium with GGT
concentrations (Lee et al, 2006). These results led Lee and Jacobs
(2009) to hypothesise that serum GGT within the reference range
was a marker of exposure to environmental pollutants. When
creatinine-adjusted urinary cadmium levels were measured in a
case–control study of 246 women with breast cancer and 254
age-matched population controls, there was a two-fold increase in
risk of breast cancer in those women with cadmium levels in the
highest quartile (McElroy et al, 2006). On this basis, GGT could
reflect previous exposure to as yet unknown carcinogens initiating
breast carcinogenesis.
It is of particular interest that GGT is associated with increased risk
when the woman is premenopausal. In addition, GGT did not seem to
be associated with an increased risk for other cancers in this cohort.
This raises the possibility of identifying those women with high
normal or elevated serum levels. In the absence of evidence of alcohol
abuse, these could be selected for closer surveillance. The method of
surveillance is still uncertain. Routine clinical examination has not
been shown to reduce mortality from breast cancer, nor has
mammography in younger women. A recent Consensus Conference
on high-risk women, mostly because of their family history, advised
that breast magnetic resonance imaging should be performed
annually but not before the age of 25 years (Schwartz et al, 2008).
If these findings can be replicated in a larger study, they may afford a
new and inexpensive opportunity to delineate women who are at high
risk of breast cancer with the hope of targeting surveillance, allowing
an earlier diagnosis and thereby reducing the mortality accruing from
this disease.
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